Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product can...
FY 2025
Mar 31, 2026
Q4 2025
Q3 2025
Nov 12, 2025
Q2 2025
Aug 14, 2025
Q1 2025
May 12, 2025